AIDS.GOV | SERVICE LOCATOR | SEARCH

BLOG.AIDS.GOV

MENU

Clinical Trials

HIV Vaccine Awareness Day

Dr. Anthony Fauci

Watch NIAID Director Anthony S. Fauci, M.D., discuss current HIV vaccine research approaches. Developing a safe and sufficiently effective HIV vaccine is essential if we are to achieve a timely and durable end to the global HIV/AIDS pandemic. The path to an HIV vaccine has not been—and will not be—an easy one. In the 27…

NIH Names Leadership, Research Units for Restructured HIV/AIDS Clinical Trials Networks

nih logo

The National Institute of Allergy and Infectious Diseases (NIAID) has selected the principal investigators and clinical trials units (CTUs) that will lead and conduct the research of the five restructured HIV/AIDS clinical trials networks through 2021. The new structure is designed to create a broader, more flexible and more collaborative approach to the networks’ research priorities, which…

NIH Statement on World AIDS Day 2013

NIH logo

In the 25 years that have passed since the first annual commemoration of World AIDS Day, extraordinary scientific progress has been made in the fight against HIV/AIDS. That progress has turned an HIV diagnosis from an almost-certain death sentence to what is now for many, a manageable medical condition and nearly normal lifespan. We have…

Study finds first evidence that PrEP can reduce HIV risk among people who inject drugs

CDC Logo

Daily HIV medications now proven to prevent HIV among all groups at high risk A daily dose of a medication used to treat HIV infection reduced the risk of HIV acquisition among people who inject drugs by 49 percent. Those who took the medication most consistently had even higher levels of protection, according to a…

Statement: NIH Discontinues Immunizations in HIV Vaccine Study

NIAID

The National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, will stop administering injections in its HVTN 505 clinical trial of an investigational HIV vaccine regimen because an independent data and safety monitoring board (DSMB) found during a scheduled interim review that the vaccine regimen did not prevent HIV infection nor…

Daily-use HIV Prevention Approaches Didn’t Work for African Women in the VOICE Study

blog.aids.gov

According to findings of a major HIV prevention trial presented Monday, March 4, 2013 at the 20th Conference on Retroviruses and Opportunistic Infections (CROI), study participants who received daily oral pre-exposure prophylaxis (PrEP) did not experience any protection against HIV compared to those in the placebo arm, likely because very few were taking the study…

NIAID Advances Efforts to Restructure Clinical Trials Networks with Funding Announcements

NIAID wordle

Over the past year and a half, many of you followed the AIDS.gov blog post series Future Directions for NIAID HIV Research by Dr. Carl Dieffenbach, Director of the Division of AIDS, National Institute of Allergy and Infectious Diseases (NIAID) at NIH. Last week, NIAID advanced those efforts by issuing several requests for applications (RFAs)…

Community Engagement in NIAID’s HIV/AIDS Clinical Trials Networks

Future Directions for NIAID HIV Research: Consider and Comment

Since early in the HIV/AIDS epidemic, the National Institute of Allergy and Infectious Diseases (NIAID) has involved community representatives and advocates in the research process.   The nature and scope of the community’s involvement have grown over the years, but the rationale behind these efforts remains the same:  the people who might benefit from the research…

Page 1 of 3123